Literature DB >> 15606375

Surgery for gastroenteropancreatic tumours in multiple endocrine neoplasia type 1: review and personal experience.

F Tonelli1, G Fratini, A Falchetti, G Nesi, M L Brandi.   

Abstract

Multiple endocrine neoplasia type 1 (MEN1) gastro-entero-pancreatic (GEP) tumours develop from the pancreatic islets and from the endocrine cells of the duodenal and gastric mucosa. Even if GEP tumours have generally a benign course, a subgroup of them shows an aggressive behaviour and is a major cause of death amongst MEN1 patients. Diagnosis of insulinoma should lead promptly to pancreatic surgery. MEN1 gastrinomas are multiple and almost exclusively localized in the duodenum. Cure rate for Zollinger-Ellison syndrome in MEN1 is low when surgery is limited to tumour enucleation or full thickness duodenal wall resection. Conversely, pancreatoduodenectomy is followed by higher chance of cure. For nonfunctioning tumours exceeding 1 cm diameter in size a prompt treatment is recommended due to their high malignant potential. Gastroscopic surveillance is indicated for the frequent occurrence of multiple, small, type 2 fundic carcinoids. Endoscopic removal is possible for lesions growing in the mucosa-submucosa, but partial or even total gastrectomy is recommended for the small number of gastric carcinoids infiltrating the muscular layers.

Entities:  

Mesh:

Year:  2005        PMID: 15606375     DOI: 10.1111/j.1365-2796.2004.01424.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  12 in total

Review 1.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

2.  Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1.

Authors:  Maria A Kouvaraki; Suzanne E Shapiro; Gilbert J Cote; Jeffrey E Lee; James C Yao; Steven G Waguespack; Robert F Gagel; Douglas B Evans; Nancy D Perrier
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

3.  Lymph nodes metastasis and recurrences justify an aggressive treatment of gastrinoma.

Authors:  Francesco Giovinazzo; Giovanni Butturini; Daniela Monsellato; Giuseppe Malleo; Giovanni Marchegiani; Claudio Bassi
Journal:  Updates Surg       Date:  2013-02-16

4.  Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1.

Authors:  Caroline L Lopez; Jens Waldmann; Volker Fendrich; Peter Langer; Peter H Kann; Detlef K Bartsch
Journal:  Langenbecks Arch Surg       Date:  2011-07-30       Impact factor: 3.445

Review 5.  Biliary tree gastrinomas in multiple endocrine neoplasia type 1 syndrome.

Authors:  Francesco Tonelli; Francesco Giudici; Gabriella Nesi; Giacomo Batignani; Maria Luisa Brandi
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

Review 6.  Multiple Endocrine Neoplasia: Genetics and Clinical Management.

Authors:  Jeffrey A Norton; Geoffrey Krampitz; Robert T Jensen
Journal:  Surg Oncol Clin N Am       Date:  2015-07-27       Impact factor: 3.495

7.  Gastroenteropancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1.

Authors:  Francesco Tonelli; Francesco Giudici; Francesca Giusti; Maria Luisa Brandi
Journal:  Cancers (Basel)       Date:  2012-05-07       Impact factor: 6.639

8.  Nonfunctional pancreatic endocrine tumor in the peripancreatic region in a Chinese patient with multiple endocrine neoplasia type 1.

Authors:  Bao-Ping Wang; Wei-Jun Tian; Jie Zhang; Chang-Xin Jiang; Hui-Qi Qu; Mei Zhu
Journal:  J Int Med Res       Date:  2017-09-14       Impact factor: 1.671

9.  Diagnosis and Treatment of Gastrinomas in Multiple Endocrine Neoplasia Type 1 (MEN-1).

Authors:  Ursula Plöckinger
Journal:  Cancers (Basel)       Date:  2012-01-20       Impact factor: 6.639

Review 10.  Surgical management of pancreatico-duodenal tumors in multiple endocrine neoplasia syndrome type 1.

Authors:  Göran Akerström; Peter Stålberg; Per Hellman
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.